Randomized trials in oncology: A fertile ground for controversy Maurie Markman Editor’s Commentary Pages: 347 - 348
Rituximab and CHOP for elderly patients with diffuse large B-cell lymphoma Carol S. Portlock Clinical Trials Report Pages: 357 - 357
Rituximab for lymphocyte-predominant Hodgkin’s disease Carol S. Portlock Clinical Trials Report Pages: 358 - 358
Posttransplant lymphoproliferative disease: Pathogenesis, monitoring, and therapy Richard F. Ambinder OriginalPaper Pages: 359 - 363
New strategies in radioimmunotherapy for lymphoma Neeta Pandit-TaskarPaul A. HamlinChaitanya R. Divgi OriginalPaper Pages: 364 - 371
Simian virus 40 and its association with human lymphomas Regis A. VilchezJanet S. Butel OriginalPaper Pages: 372 - 379
Early blast clearance by remission induction as a prognostic factor in acute myeloid leukemia Elihu H. Estey Clinical Trials Report Pages: 389 - 389
Adaptive randomization in a treatment study of patients with adverse karyotype acute myeloid leukemia Elihu H. Estey Clinical Trials Report Pages: 390 - 390
Monitoring AML1-ETO and CBFΒ-MYH11 transcripts in acute myeloid leukemia John A. Liu YinLindsay Frost OriginalPaper Pages: 399 - 404
Monitoring of acute myeloid leukemia by flow cytometry Wolfgang KernSusanne Schnittger OriginalPaper Pages: 405 - 412
Immunologic monitoring in adults with acute lymphoblastic leukemia María-Belén VidrialesAlberto OrfaoJesÚs F. San-Miguel OriginalPaper Pages: 413 - 418
Immunologic monitoring in chronic lymphocytic leukemia William G. Wierda OriginalPaper Pages: 419 - 425
Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia Vivian G. OehlerJerald P. Radich OriginalPaper Pages: 426 - 435